The short‐term effects of tolterodine on nocturnal incontinence after ileal orthotopic neobladder: a randomised crossover placebo‐controlled study

Objectives To assess the effect of tolterodine in the treatment of nocturnal urinary incontinence (NUI) after ileal orthotopic neobladder (ONB). Patients and methods This is a prospective randomised placebo‐controlled crossover study (clinicaltrials.gov: NCT02877901). Patients with NUI after ONB wer...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2019-10, Vol.124 (4), p.679-686
Main Authors: Zahran, Mohamed H., Harraz, Ahmed M., Taha, Diaa Eldin, Nabeeh, Hossam, El Hefnawy, Ahmed S., Ali‐El‐Dein, Bedeir
Format: Article
Language:English
Subjects:
anticholinergics
ileal orthotopic neobladder
Long-term effects
nocturnal incontinence
radical cystectomy
tolterodine
Urinary incontinence
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To assess the effect of tolterodine in the treatment of nocturnal urinary incontinence (NUI) after ileal orthotopic neobladder (ONB). Patients and methods This is a prospective randomised placebo‐controlled crossover study (clinicaltrials.gov: NCT02877901). Patients with NUI after ONB were randomly allocated into two equal groups. Group T received 4 mg extended‐release tolterodine at bed‐time and Group P received placebo for 4 weeks followed by 2 weeks of washout, then crossed over to the alternate therapy for 4 weeks. Patients were assessed by the number of pads used per night (PPN) and with the Arabic version of the International Consultation on Incontinence Modular Questionnaire‐Short Form (ICIQ‐SF) at both phases of the study. The outcomes were the rate of NUI improvement and medication adverse events. Results Out of 172 patients, 150 and 122 patients were evaluated at both phases of the study. The mean ICIQ‐SF scores and PPN were significantly decreased in Group T compared to Group P in both study phases (P 
ISSN:1464-4096
1464-410X
DOI:10.1111/bju.14769